BSX · Full Picture

BOSTON SCIENTIFIC CORP — the full picture

Earnings window · 2026-07-13 to 2026-09-24 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 93
    +16.0% assets; 3 sources (news, press_release, sec_filing); 3 forward row(s); structured_verified
    Boston Scientific announced on January 15, 2026 a definitive agreement to acquire 100% of Penumbra for $374 per share, or approximately $14.500 billion, with the transaction expected to be completed in the second half of 2026 subject to customary closing conditions including regulatory clearances.
  2. Liquidity and Cash Position · Liquidity & cash positionPriority 78
    -12.2% liability; 1 forward row(s); structured_verified
    On February 26, 2026, Boston Scientific entered into a $2.000 billion 364-day revolving credit agreement and a $6.000 billion term loan credit agreement that permit up to a $1.000 billion Tranche A Loan and up to a $5.000 billion Tranche B Loan, each drawable only upon closing of the pending Penumbra acquisition and maturing 364 days thereafter.
  3. Revenue Performance and Mix · Revenue growth & mixPriority 71
    +30.9% revenue (realized); 3 sources (news, press_release, sec_filing); quote_verified
    Reported net sales of $5.442 billion represented an increase of 7.5 percent on a reported basis compared to the company's guidance range of 5.5 to 7.5 percent.
  4. Stock Repurchase Program · Buybacks & dividendsPriority 68
    -4.4% cash (realized); 3 sources (news, press_release, sec_filing); 1 forward row(s); structured_verified
    Boston Scientific announced an accelerated share repurchase program of $2.000 billion.
  5. Restructuring Charges · Restructuring & impairmentPriority 63
    -2.3% operating_income; 3 sources (news, press_release, sec_filing); 3 forward row(s); quote_verified
    Boston Scientific announced a new global restructuring plan expected to result in pre-tax charges of $700-800 million and annual pre-tax savings of $500 million.
  6. Market Demand Trends · Demand, orders & backlogPriority 62
    2 sources (news, sec_filing); 1 forward row(s); quote_verified
    The global cardiovascular devices market is projected to grow from $72.4 billion in 2025 to $101.6 billion by 2030.
  7. Income Tax Rate Changes · TaxPriority 60
    +7.1% net_income (realized); 2 sources (press_release, sec_filing); structured_verified
    In the first six months of 2026, the principal reason for the difference between the tax rate from continuing operations and the reported tax rate relates to a discrete tax benefit of $384 million to reflect a change in the anticipated future tax rate at which we expect to recover certain capitalized expenses.
  8. Regulatory Risk · Regulatory action & investigationsPriority 60
    1 forward row(s); quote_verified
    Boston Scientific and Penumbra each received a Second Request from the U.S. Federal Trade Commission on March 16, 2026 in connection with the FTC's review of the acquisition, and the companies are responding and working cooperatively with the FTC.
  9. Guidance / Outlook · Guidance & outlookPriority 55
    2 sources (news, press_release); 6 forward row(s); quote_verified
    Boston Scientific lowered its 2026 revenue outlook to 5%–6% from an initial 10%–11%.
  10. Capital Return Program · Buybacks & dividendsPriority 54
    1 forward row(s); quote_verified
    BOSTON SCIENTIFIC CORP's board authorized a $5 billion share-repurchase program.
  11. Operating Cash Flow and Capex · Capital expenditurePriority 51
    quote_verified
    For the six months ended June 30, 2026, cash provided by operating activities was $1,822 million, cash used for investing activities was $(2,547) million, and cash used for financing activities was $(670) million.
  12. Operating Income and Margins · Operating income & profitabilityPriority 50
    +9.2% operating_income (realized); quote_verified
    Fiscal 2025 operating income rose around 20% to $3.0 billion.

Threads by pillar

Revenue & Demand Priority 83 · 7 threads

Costs & Margins Priority 77 · 6 threads

Capital & Balance Sheet Priority 90 · 6 threads

Strategy & Portfolio Priority 93 · 1 thread

Legal, Regulatory & Policy Priority 68 · 6 threads

Guidance & Outlook Priority 55 · 1 thread

Macro & Market Conditions Priority 42 · 1 thread

Management & Governance Priority 48 · 3 threads

Unclassified Priority 37 · 3 threads

Expected impact by metric

metricforward netforward grossrealized
assets+16.0%+16.0%—
liability-12.2%+12.2%—
operating_income-2.3%+11.5%+7.6%
margin——+5.7%
cash——-7.0%
net_income——+7.1%
revenue——+30.9%